Crispr Therapeutics AG (CRSP) — Cash Flow-to-Debt Ratio
Crispr Therapeutics AG (CRSP) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2026, meaning its operating cash flow of $-108.90 Million could theoretically repay 0% of its total liabilities ($911.26 Million) in one year. Explore Crispr Therapeutics AG (CRSP) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Crispr Therapeutics AG Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Crispr Therapeutics AG across 12 annual periods. Also explore balance sheet size of Crispr Therapeutics AG for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Crispr Therapeutics AG (2014–2025)
Year-by-year debt coverage analysis for Crispr Therapeutics AG. For market capitalisation and broader financial context, see how much is Crispr Therapeutics AG worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.00x | $-345.01 Million | $343.43 Million | ▼ -118.1% |
| 2024 | -0.46x | $-142.77 Million | $309.95 Million | ▲ +38.7% |
| 2023 | -0.75x | $-260.38 Million | $346.77 Million | ▲ +44.3% |
| 2022 | -1.35x | $-495.74 Million | $367.58 Million | ▼ -188.2% |
| 2021 | 1.53x | $538.97 Million | $352.42 Million | ▲ +205.1% |
| 2020 | -1.46x | $-238.37 Million | $163.73 Million | ▼ -427.1% |
| 2019 | 0.45x | $56.68 Million | $127.33 Million | ▲ +144.8% |
| 2018 | -0.99x | $-96.24 Million | $96.82 Million | ▼ -18.4% |
| 2017 | -0.84x | $-70.10 Million | $83.51 Million | ▼ -70.1% |
| 2016 | -0.49x | $-55.31 Million | $112.12 Million | ▼ -256.5% |
| 2015 | 0.32x | $59.43 Million | $188.55 Million | ▲ +155.9% |
| 2014 | -0.56x | $-4.79 Million | $8.50 Million | — |